Fewer than a tenth of people that would benefit from obesity jabs such as Wegovy are able to get them, states the WHO as it releases its first recommendations on the medications.
Considering in excess of 1,000,000,000 people worldwide now obese, it is urging more widespread and fairer availability to these injectable treatments.
According to estimates, over two billion will be living with obesity by 2030 without intervention.
"The latest guidance affirms that excess weight is a long-term condition that can be managed with holistic and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are significant barriers to broad access to the injections that can help people shift significant body mass, explains the organization.
Weight-Loss Drug Supply Crisis
Even under the current most optimistic case, the production of these medications could only cover approximately 100 million people – less than 10% of those who need them, per the health organization.
The guideline encourages countries and companies to widen availability, through measures including licensing agreements.
The intellectual property rights on the active ingredient – the core ingredient of a leading brand – is set to lapse in several countries in 2026.
How Weight-Loss Drugs Function
These medications mimick a body's own hormone to slow digestion, reduce hunger and enhance satiety so people reduce food intake.
Individuals usually begin shedding pounds within a few weeks of starting on the once-weekly jabs.
Research suggests people may regain a significant portion a year later of discontinuing the drug, when their typical food cravings come back.
Being above a healthy weight raises your likelihood for experiencing diseases, such as type 2 diabetes, heart disease, brain attack, and some malignancies.
Obesity impacts people in all nations and was associated with over three and a half million fatalities worldwide in 2024, per the WHO.
